Skip to main content

Table 2 SVF cell therapy and outcomes

From: RETRACTED ARTICLE: Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study

Case Age/gender Diagnosis Cells (mln.) administered per procedure (numbers of procedure) Time after procedure (months) Clinical symptom, ulcer healing Claudication (m) ABI improvement (%)
1 (L) 35/M ASO 40 (2) 12 Improved, ulcer healed 500–600 48
2 (R) 70/M ASO 56 (2) 12 Improved 300–350 23
3 (L) 68/M ASO 32 (1) 12 Improved 250–300 18
4 (L) 52/M ASO 55 (2) 12 Improved 400–450 40
5 (R) 59/M ASO 38 (2) 12 Improved 300–350 35
6 (Lu) 77/F ASO 45 (2) 12 Improved
7 (L) 77/F ASO 42 (1) 12 Improved, ulcer healed 150–200 17
8 (R) 67/M ASO 56 (2) 12 Improved, ulcer healed 200–250 29
9 (L) 60/F ASO 36 (2) 12 Improved 300–350 37
10 (R) 68/F ASO 32 (1) 1 week Major amputation, wound healed
11 (L) 60/M ASO 43 (2) 12 Improved, ulcer healed 300–350 25
12 (R) 56/M ASO 51 (1) 12 Improved, ulcer healed 300–350 23
13 (L) 67/M ASO 39 (2) 12 Improved 300–350 28
14 (R) 72/F ASO 33 (1) 12 Improved 250–300 25
15 (R) 64/M ASO 34 (1) 2 weeks Major amputation, wound healed
  1. Lu left upper limb, L left lower limb, R right lower limb, ASO arteriosclerosis obliterans